Dergiler / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 2

Clinical course of COVID-19 disease in immunosuppressed renal transplant patients

Sayfa
428–434
Yayın Tarihi
2022-11-06
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

It can be said that discontinuation or reducing dosages of immunosuppressives may be effective and safe in kidney transplant patients.Key words: COVID-19, SARS-CoV-2, kidney transplantation, immunosuppression, mortality, acute rejection

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: We aimed to identify clinical settings of renal transplant patients with COVID-19.
📊
Temel Bulgular & Veri:Materials and methods: In this retrospective study, we included kidney transplant inpatients with laboratory confirmed COVID-19 who had been discharged or had died by October 1st, 2020.
💡
Sonuç & Katkı:It can be said that discontinuation or reducing dosages of immunosuppressives may be effective and safe in kidney transplant patients.Key words: COVID-19, SARS-CoV-2, kidney transplantation, immunosuppression, mortality, acute rejection
🔬Tür:Araştırma Makalesi
📍Kapsam:2020 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: We aimed to identify clinical settings of renal transplant patients with COVID-19. Materials and methods: In this retrospective study, we included kidney transplant inpatients with laboratory confirmed COVID-19 who had been discharged or had died by October 1st, 2020. Characteristics of the patients, including basal and last outpatient biochemical parameters were recorded. Discontinuation or dosage reduction of immunosuppressives and other treatment information was documented. Results: Twenty patients were included in this study, of whom 18 were discharged and 2 died in hospital. The mean duration of hospitalization and follow-up were 9.7 ± 6.4 days and 4.5 ± 2.0 months, respectively. Fourteen patients (70%) were male and mean age was 48.0 ± 10.3 years. At admission, all had immunosuppression withdrawn and were started on methylprednisolone 16 mg/ day (50%) or dexamethasone (50%). Tacrolimus/m-TOR inhibitors were reduced by 50% and all antimetabolites were discontinued. Hemodialysis was needed for 10% of patients. Acute kidney injury was detected in 25% of the patients. With respect to hospitalization time and complications, there was no significant difference between patients who used dexamethasone and those who did not (P > 0.05). The discontinued immunosuppressives were resumed within 2 to 4 weeks after discharge according to the severity of disease. No rehospitalization or acute rejection was detected during the follow-up of the patients.Conclusion: Renal transplant patients are considered a high risk group for COVID-19. It can be said that discontinuation or reducing dosages of immunosuppressives may be effective and safe in kidney transplant patients.Key words: COVID-19, SARS-CoV-2, kidney transplantation, immunosuppression, mortality, acute rejection

🔖

Bu Makaleye Atıf Yap

YAYLACI, S., TOMAK, Y., KÖROĞLU, M., GENÇ, A. B., DHEİR, H., MURATDAĞI, G., KARABAY, O., ÇETİN, E. S., SİPAHİ, S., ÖZMEN, K., FİRAT, N., ATEŞ, Ö. F. (2022). Clinical course of COVID-19 disease in immunosuppressed renal transplant patients. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 2, 428–434. https://ajindex.com/articles/611561

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (1)

  1. Jing Y, Ya Z, Xi G, Ke P, Zhaofeng C et al. Prevalence of comorbidities and its effects in patients infected with SARSCoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases 2020; 94: 91-95. doi: 10.1016/j. ijid.2020.03.017 2. Zhang H, Chen Y, Yuan Q, Xia Q-X, Zeng X-P et al. Identification of kidney transplant recipients with Coronavirus disease 2019. European Urology 2020; 77: 742-747. doi: 10.1016/j.eururo.2020.03.030 3. Guillen E, Pineiro GJ, Revuelta I, Rodriguez D, Bodro M et al. Case report of COVID‐19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? American Journal of Transplantation 2020; 20: 1875-1878. doi: 10.1111/ ajt.15874 4. Fernández‐Ruiz M, Andrés A, Loinaz C, Delgado JF, López‐ Medrano F et al. COVID‐19 in solid organ transplant recipients: a single‐center case series from Spain. American Journal of Transplantation 2020; 20: 1849-1858. doi: 10.1111/ ajt.15929 5. Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M et al. Covid-19 and kidney transplantation. New England Journal of Medicine 2020; 382: 2475-2477. doi: 10.1056/NEJMc2011117 6. Boyarsky BJ, Chiang TP, Werbel WA, Durand CM, Avery RK et al. Early impact of COVID‐19 on transplant center practices and policies in the United States. American Journal of Transplantation 2020; 20: 1809-1818. doi: 10.1111/ajt.15915 7. Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F et al. Management of patients on dialysis and with kidney transplantation during the SARS-CoV-2 (COVID-19) pandemic in Brescia, Italy. Kidney International Reports 2020; 5: 580-585. doi: 10.1016/j.ekir.2020.04.001 8. Willicombe M, Thomas D, McAdoo S. COVID-19 and calcineurin inhibitors: should they get left out in the storm?. Journal of the American Society of Nephrology 2020; 31: 1145- 1146. doi: 10.1681/ASN.2020030348 9. Shetty R, Ghosh A, Honavar SG, Khamar P, Sethu S. Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: present and future. Indian Journal of Ophthalmology 2020; 68: 693-702. doi: 10.4103/ijo.IJO_639_20 10. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New England Journal of Medicine 2020; 382: 2411- 2418. doi: 10.1056/NEJMoa2012410 11. Peter H, Wei S L, Jonathan R E, Marion M, Jennifer L B et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. New England Journal of Medicine 2020; 384: 693-70